Very astute, Gfp. He was also head of neuroscience at Lilly before moving on to Amgen, so one can see an AMPA connection there as well. I would think Biovail would have interest--but they are not interested in discovery-stage work. It would seem a near-ideal scenario, but Biovail's avowed disinclination to get into anything not already in the clinic is a cautionary note. I do not know the likelihood of this turning into anything.
Market Data 
Markets 
AI
